Intensive Care Research - Call for Papers for the Special Issue: Multidrug-resistant bacteria in ICU

Guest Editor: 

Prof. Yimin Li

Aims and scope

A rising spread of antibiotic-resistant microorganisms led bacterial infections to become a major threat to global health, which is anticipated to cause more than 10 million annual deaths worldwide in 2050. Specifically, Infections by multidrug resistant bacteria (MDR) occur frequently in patients admitted to intensive care unit (ICU) and are usually associated to a high mortality and morbidity and a higher patient care cost. ICU patients are particularly prone to MDR infections due to performance of invasive procedures, impairment of protective mechanisms such as cough reflex, the dysfunction of immune system caused by primary hits such as trauma and extensive antibiotic use. In this special issue, we aim to provide a communication platform for interdisciplinary researchers to address all aspect of MDR infection in ICU patient.

Main topics and quality control

We welcome Reviews, Original Research and other article types. We expect submissions relating, but not limited to, the following themes:

• The prevalence of MDR, the Spectrum of Multidrug-resistant microorganisms, and Patient cost for MDR infection.
• The independent risk factors for occurrence of infections by MDR bacteria among ICU patients, and impact of MDR on the patient’s outcome.
• Development of accurate scores or predicting model for colonization or infection of MDR, metrics for predicting therapeutic efficacy and the prognostic model for patient outcome.
• Insights in the mechanisms that are associated with the spread of MDR pathogens and strategies to prevent the cross-transmission of nosocomial MDR and to better control spread of MDR.
• Appropriate use of antibiotics and antibiotic stewardship for the treatment for MDR infection in ICU.
• The development of new therapeutic methods for MDR treatment, including development of novel molecules and new antibiotic, immune-modulating therapies to boost the innate and adaptive immunity or treatment of immune-dysfunction, adjunctive therapies in MDR infections.

Full papers will be subject to a strict review procedure for final selection to this special issue based on the following criteria:

1. The manuscript must be original, with sufficient novelty, scientific accuracy, clinical (or scientific) importance, and will be of interest for the Journal readers.
2. Relevance to the topic of the special issue.
3. Presence of the following statements (if applicable): disclosure of potential conflicts of interest, approval by a local ethics committee (for both human as well as animal studies), informed consent for research involving human participants, registration of clinical trials.

Important date

Open date:                                     18 April 2022

Submit your paper

All papers have to be submitted via the Editorial Manager online submission and peer review system. Instructions will be provided on screen and you will be stepwise guided through the process of uploading all the relevant article details and files associated with your submission. During submission authors should indicate that their manuscript belongs to the special issue “Multidrug-resistant bacteria in ICU” (this question will appear at “Additional Information” step). All manuscripts must be submitted in English.

To access the online submission site for the journal, please visit https://www.editorialmanager.com/icrs/default1.aspx (this opens in a new tab). Note that if this is the first time that you submit to the Intensive Care Research, you need to register as a user of the system first.

NOTE : Before submitting your paper, please make sure to review the journal's Author Guidelines (this opens in a new tab) first.

After acceptance

This special issue will be published as a virtual collection that will be accessible at SpringerLink.  

Accepted papers will be published online within about 20 days after acceptance, fully citable by DOI (Digital Object Identifier), prior to publication in the issue.”

Introduction of the Guest Editor

[Yimin Li]

Dr. Yimin Li, Professor, MD, mentor of doctorate candidates, chief physician, and executive president of the First Affiliated Hospital of Guangzhou Medical University. He is the standing member of Branch of Critical Care Medicine, Chinese Medical Association, Chairman of Branch of Critical Care Medicine, Guangdong Medical Association. Dr. Li has 36-year experiences of first-line clinical work in Respiratory and Critical Care Medicine and has specialized in clinical, basic, and translational research related to critical illness. Dr. Li has a total of more than 100 published articles in SCIE-indexed journals.